A Phase III, International, Randomised, Double Blind, Parallel-Group Study to Assess the Efficacy of Zactima Versus Tarceva in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Failure of at Least One Prior Chemotherapy.
Phase of Trial: Phase III
Latest Information Update: 27 Jan 2018
At a glance
- Drugs Vandetanib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms ZEST
- Sponsors Sanofi Genzyme
- 31 Aug 2018 Biomarkers information updated
- 15 Nov 2016 Status changed from active, no longer recruiting to completed.
- 25 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Dec 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History